The product designation “Quinolone Premix Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions” describes a concentrated enrofloxacin base or monohydrate intermediate milled for downstream incorporation into multiple finished dosage forms. The pharmacopoeial entity is 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, with a relative molecular mass of 359.4 and a zwitterionic structure that produces strongly pH-dependent aqueous solubility. Commercial model designations for the API are vendor-specific and usually encode the active moiety and particle-size class; a coarse premix fraction, a micronised tablet fraction, and an injectable fraction may be assigned different article codes, but no single model code is harmonised across distributors. The definitive specification remains the certificate of analysis. The material is not a finished premix; it is the active input used to manufacture 2.5%, 5%, 10%, and 20% medicated premixes, oral powders, granules, tablets, capsules, and injectable solutions. Dissolution in aqueous systems requires pH adjustment below 5.0 or above 9.0; the region of lowest solubility occurs near the isoelectric point. A premix-grade API certificate of analysis should include assay, related substances, water content, sulphated ash, heavy metals, residual solvents, and particle-size distribution. The product is packaged in double polyethylene bags inside a fibre drum or in aluminium-laminated sacks for moisture protection; the drum net weight is typically 25 kg for non-sterile premix grade.

What compendial limits separate a veterinary premix-grade quinolone from an unqualified technical powder?

The distinction is established through pharmacopoeial test methods and residual solvent control under VICH GL18. The following certificate-of-analysis profile is typical for premix-grade enrofloxacin API intended for non-sterile veterinary dosage forms.

For injectable-grade material, bacterial endotoxins are tested according to Ph. Eur. 2.6.14; the limit is calculated from the maximum intended dose. Non-sterile premix grade is not automatically suitable for injection. Residual solvent control under VICH GL18 is aligned with ICH Q3C but is implemented within the veterinary marketing authorisation dossier. Published data for a single vendor’s model-specific certificate of analysis is limited; therefore the purchaser should compare the actual certificate of analysis against the pharmacopoeial monograph and the intended dosage form.

During tablet and capsule manufacture, the premix-grade quinolone API is dry-blended with lactose monohydrate, microcrystalline cellulose, crospovidone, and magnesium stearate. Direct compression is feasible when the D90 of the API is below 150 µm and the bulk density falls within 0.45–0.65 g/mL; however, published data for a specific enrofloxacin premix on a production-scale rotary tablet press is limited. A rotary tablet press with forced feeders and main compression force of 15–25 kN is used in many veterinary formulations. Blend uniformity is verified according to USP <905> or Ph. Eur. 2.9.40; an acceptance value below 15 is required. Tablet hardness of 60–80 N and disintegration below 15 min in 0.1 M hydrochloric acid at 37°C are typical release targets. Capsule filling on automatic dosator machines requires a Carr index below 25 to avoid rat-holing and weight variation; pre-sieving through a 0.5 mm screen removes agglomerates. The operational boundary for relative humidity is 60%; above this value the powder should be pre-dried to water content ≤ 1.0% per Ph. Eur. 2.5.12 before compression.

Wet granulation limits for enrofloxacin premix powders in high-shear mixers

Aqueous granulation of the zwitterionic API can produce partial dissolution and recrystallisation on drying, altering particle habit and tablet dissolution. High-shear mixers with impeller tip speeds below 5 m/s and chopper operation below 2 min are used when dry granulation is not acceptable. The granulating fluid is preferably anhydrous ethanol or isopropanol; if water is required, the moisture addition is held below 10% w/w of dry mass and the wet mass is discharged immediately. Fluid-bed drying inlet air is maintained below 60°C because higher temperatures may accelerate hydrate conversion; published data for this specific hydrate transition in enrofloxacin premix granules is limited. Dried granules are milled through a 0.8 mm screen and blended with external disintegrant. Final water content is rechecked by Ph. Eur. 2.5.12; a limit of ≤ 1.0% is applied. Magnesium stearate is added at 0.5–1.0% w/w in the final blending step; prolonged blending above 10 min is avoided because hydrophobic film formation can retard dissolution.

Injectable solutions prepared from premix-grade quinolone API require a dedicated injectable grade with controlled bacterial endotoxins and bioburden. The vehicle is water for injection adjusted to pH 3.8–4.5 with hydrochloric acid or methanesulfonic acid; the API is dissolved before any pH increase to avoid localised precipitation. Terminal moist-heat sterilisation at 121°C for 15 min is validated only for formulations that remain clear at pH 3.8–4.5; precipitation during the autoclave cycle requires reformulation or aseptic filtration. Multivalent cations liberated from raw water, glass, or elastomeric closures must be controlled; concentrations of magnesium, aluminium, and iron should be below 0.05 mg/L to prevent quinolone chelation. Filtration through a polyvinylidene fluoride membrane of 0.22 µm pore size is performed prior to filling. Particulate matter is evaluated according to USP <788>; the limit is container-volume dependent. Sterility testing is performed according to Ph. Eur. 2.6.1. The injectable-grade API should also be tested for bacterial endotoxins according to Ph. Eur. 2.6.14; the limit is calculated from the maximum intended dose per animal body weight.

When the premix API is dispersed into feed premixes and oral solutions, polyvalent carriers change the dissolution profile

The quinolone premix API chelates with polyvalent cations in feed matrices, particularly calcium, magnesium, aluminium, and iron. Carriers such as limestone, dicalcium phosphate, bentonite, and aluminium silicate reduce oral absorption and must be avoided unless the finished feed formula has been specifically evaluated for bioequivalence. Lactose monohydrate, dextrose, and starch-based carriers are preferred. For feed premix manufacturing, a ribbon mixer with tip speed below 1.5 m/s and a mixing time of 10–15 min is used; blend uniformity RSD below 5.0% is required and is verified according to Ph. Eur. 2.9.40. Final feed concentrations are species-specific; in the United States, authorised conditions for enrofloxacin are listed in FDA 21 CFR 520.812, and extralabel use of fluoroquinolones in food-producing animals is prohibited under FDA 21 CFR 530.41. The premix API itself contains no carriers, flavours, or masking agents; the final dosage form manufacturer assumes responsibility for blend uniformity, potency, and stability. In oral solution concentrates, the API is dissolved at pH 3.5–4.5 and protected from light; the reconstituted solution is typically used within 24 h at 25°C. Multivalent cation contamination from hard water used for reconstitution may reduce activity; water hardness below 50 mg/L calcium carbonate equivalent is recommended.

Powder and granule premixes intended for oral administration through drinking water or feed differ from tablet-grade API principally in particle-size distribution and dust control. A coarse fraction with D90 ≤ 150 µm is preferred for premix blending; a second fraction with D90 between 150 µm and 300 µm may be used for granule carriers. Micronised material with D90 ≤ 10 µm is reserved for tablets and capsules because it improves content uniformity but increases electrostatic adhesion. Oral powder for reconstitution is typically packed in sachets containing 10% enrofloxacin w/w; the powder is diluted in 10–50 L of drinking water and stirred until clear. Oral solution concentrates containing 10% enrofloxacin are adjusted to pH 3.5–4.5; antioxidant use is not universally required, but sodium metabisulfite can be included at 0.1% w/v if justified by stability data. The main difference from finished premixes is that the API is a single chemical entity, whereas finished premixes are formulated mixtures containing carriers, stabilisers, and sometimes flavouring agents. The API supplier does not provide the final marketing authorisation; the dosage form manufacturer performs the stability and homogeneity studies required for registration.

Differences from human-use quinolone APIs and other antibacterial premix intermediates

Human-use ciprofloxacin or levofloxacin APIs may share similar assay limits and impurity thresholds, but they are not automatically suitable for veterinary premix applications. Injectable-grade human APIs are often supplied with endotoxin and bioburden certificates that are not required for non-sterile premix grades, while veterinary premix APIs may carry different residual solvent specifications under VICH GL18. The package and labelling also differ: non-sterile veterinary premix grade is supplied in multi-layer bags or drums, whereas injectable-grade material requires containers that preserve low endotoxin and bioburden levels. The metabolic relationship between enrofloxacin and ciprofloxacin is a further distinction: enrofloxacin is partly de-ethylated to ciprofloxacin in several species, which contributes to the antimicrobial activity attributed to the parent molecule. Compared with β-lactam premix intermediates, the quinolone API is not susceptible to hydrolytic opening of a β-lactam ring and is less sensitive to acidic oral solution conditions; however, it is more sensitive to photolysis and chelation by polyvalent cations. Compared with tetracycline premixes, the quinolone premix can bind to similar clay and mineral carriers, but the clinical consequence is concentration-dependent activity and a different post-antibiotic effect. The quinolone premix should not be dry-blended with tetracycline, macrolide, or β-lactam APIs unless compatibility and stability data exist for the specific combination, because the pH and moisture microenvironments can alter dissolution and degradation kinetics. Published data for binary API premix compatibility with enrofloxacin is limited for most combinations.

Storage of the quinolone premix API at or below 25°C and relative humidity below 60% is required to maintain the water content within the certificate-of-analysis limit. The API should be kept in moisture-resistant packaging and protected from light; aqueous solutions are more photolabile than the solid powder. Revalidation of water content per Ph. Eur. 2.5.12 is recommended after the container is opened or after storage in tropical supply chains. The solid premix API should not be blended with strong bases above pH 9.0 or with oxidising agents because this may degrade the piperazine ring; published data for forced degradation of veterinary premix-grade enrofloxacin under specific storage conditions is limited. The product is not intended for direct administration; it is a manufacturing input.